Literature DB >> 17960777

Proper inference from Simon's two-stage designs.

Tatsuki Koyama1, Heidi Chen.   

Abstract

Simon's two-stage designs are very popular for phase II clinical trials. A literature review revealed that the inference procedures used with Simon's designs almost always ignore the actual sampling plan used. Reported P-values, point estimates and confidence intervals for the response rate are not usually adjusted for the design's adaptiveness. In addition, we found that the actual sample size for the second stage is often different from that planned. We present here a method for inferences using both the planned and the actual sample sizes. The conventional and the preferred inference procedures usually yield similar P-values and confidence intervals for the response rate. The conventional inference, however, may contradict the result of the corresponding hypothesis testing.

Entities:  

Mesh:

Year:  2008        PMID: 17960777      PMCID: PMC6047527          DOI: 10.1002/sim.3123

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  24 in total

1.  Optimal two-stage designs for clinical trials based on safety and efficacy.

Authors:  P F Thall; S C Cheng
Journal:  Stat Med       Date:  2001-04-15       Impact factor: 2.373

2.  Optimal two-stage designs for single arm phase II cancer trials.

Authors:  Jonathan Shuster
Journal:  J Biopharm Stat       Date:  2002-02       Impact factor: 1.051

3.  Early selection in a randomized phase II clinical trial.

Authors:  Seth M Steinberg; David J Venzon
Journal:  Stat Med       Date:  2002-06-30       Impact factor: 2.373

4.  Estimation of a parameter and its exact confidence interval following sequential sample size reestimation trials.

Authors:  Yi Cheng; Yu Shen
Journal:  Biometrics       Date:  2004-12       Impact factor: 2.571

5.  A design of phase II cancer trials using total and complete response endpoints.

Authors:  Ying Lu; Hua Jin; Kathleen R Lamborn
Journal:  Stat Med       Date:  2005-10-30       Impact factor: 2.373

6.  Optimal two-stage design for a series of pilot trials of new agents.

Authors:  T J Yao; E S Venkatraman
Journal:  Biometrics       Date:  1998-09       Impact factor: 2.571

7.  Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials.

Authors:  P F Thall; H G Sung
Journal:  Stat Med       Date:  1998-07-30       Impact factor: 2.373

8.  The bias of the sample proportion following a group sequential phase II clinical trial.

Authors:  M N Chang; H S Wieand; V T Chang
Journal:  Stat Med       Date:  1989-05       Impact factor: 2.373

9.  Optimal two-stage designs for phase II clinical trials.

Authors:  R Simon
Journal:  Control Clin Trials       Date:  1989-03

10.  An optimal two-stage phase II design utilizing complete and partial response information separately.

Authors:  Katherine S Panageas; Alex Smith; Mithat Gönen; Paul B Chapman
Journal:  Control Clin Trials       Date:  2002-08
View more
  39 in total

1.  Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: a 2-cohort, phase 2 study.

Authors:  Martee L Hensley; Sara Kravetz; Xiaoyu Jia; Alexia Iasonos; William Tew; Lauren Pereira; Paul Sabbatini; Christin Whalen; Carol A Aghajanian; Corinne Zarwan; Suzanne Berlin
Journal:  Cancer       Date:  2011-09-20       Impact factor: 6.860

2.  Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia.

Authors:  Judith E Karp; Tatiana I Vener; Mitch Raponi; Ellen K Ritchie; B Douglas Smith; Steven D Gore; Lawrence E Morris; Eric J Feldman; Jacqueline M Greer; Sami Malek; Hetty E Carraway; Valerie Ironside; Steven Galkin; Mark J Levis; Michael A McDevitt; Gail R Roboz; Christopher D Gocke; Carlo Derecho; John Palma; Yixin Wang; Scott H Kaufmann; John J Wright; Elizabeth Garret-Mayer
Journal:  Blood       Date:  2011-10-14       Impact factor: 22.113

3.  Suspension of accrual in phase II cancer clinical trials.

Authors:  Yimei Li; Rosemarie Mick; Daniel F Heitjan
Journal:  Clin Trials       Date:  2015-01-07       Impact factor: 2.486

4.  Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.

Authors:  Judith E Karp; Elizabeth Garrett-Mayer; Elihu H Estey; Michelle A Rudek; B Douglas Smith; Jacqueline M Greer; D Michelle Drye; Karen Mackey; Kathleen Shannon Dorcy; Steven D Gore; Mark J Levis; Michael A McDevitt; Hetty E Carraway; Keith W Pratz; Douglas E Gladstone; Margaret M Showel; Megan Othus; L Austin Doyle; John J Wright; John M Pagel
Journal:  Haematologica       Date:  2012-06-24       Impact factor: 9.941

Review 5.  Statistical issues for design and analysis of single-arm multi-stage phase II cancer clinical trials.

Authors:  Sin-Ho Jung
Journal:  Contemp Clin Trials       Date:  2015-03-03       Impact factor: 2.226

6.  Phase I/II Study of CPX-351 Followed by Fludarabine, Cytarabine, and Granulocyte-Colony Stimulating Factor for Children With Relapsed Acute Myeloid Leukemia: A Report From the Children's Oncology Group.

Authors:  Todd M Cooper; Michael J Absalon; Todd A Alonzo; Robert B Gerbing; Kasey J Leger; Betsy A Hirsch; Jessica Pollard; Bassem I Razzouk; Richard Aplenc; E Anders Kolb
Journal:  J Clin Oncol       Date:  2020-05-13       Impact factor: 44.544

7.  Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer.

Authors:  A J Montero; C M Diaz-Montero; Y E Deutsch; J Hurley; L G Koniaris; T Rumboldt; S Yasir; M Jorda; E Garret-Mayer; E Avisar; J Slingerland; O Silva; C Welsh; K Schuhwerk; P Seo; M D Pegram; S Glück
Journal:  Breast Cancer Res Treat       Date:  2011-12-03       Impact factor: 4.872

8.  Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.

Authors:  Jonathan W Friedberg; Daruka Mahadevan; Erin Cebula; Daniel Persky; Izidore Lossos; Amit B Agarwal; Jungah Jung; Richard Burack; Xiaofei Zhou; E Jane Leonard; Howard Fingert; Hadi Danaee; Steven H Bernstein
Journal:  J Clin Oncol       Date:  2013-09-16       Impact factor: 44.544

9.  Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer.

Authors:  B Burtness; M Gibson; B Egleston; R Mehra; L Thomas; R Sipples; M Quintanilla; J Lacy; S Watkins; J R Murren; A A Forastiere
Journal:  Ann Oncol       Date:  2009-05-08       Impact factor: 32.976

10.  Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers.

Authors:  Peter Izmirly; Mimi Kim; Deborah M Friedman; Nathalie Costedoat-Chalumeau; Robert Clancy; Joshua A Copel; Colin K L Phoon; Bettina F Cuneo; Rebecca E Cohen; Kimberly Robins; Mala Masson; Benjamin J Wainwright; Noel Zahr; Amit Saxena; Jill P Buyon
Journal:  J Am Coll Cardiol       Date:  2020-07-21       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.